Novartis in the Philippines was incorporated in 1996, following the merger of the global parent companies Ciba-Geigy and Sandoz. Novartis Healthcare Philippines, Inc. is one of the leading research-based pharmaceutical companies in the country, providing innovative, life-saving medicines to patients.

Novartis has made substantial contributions to support the Philippine economy and improve health outcomes of Filipinos:


Economy

In 2022, Novartis contributed PHP 7.5 billion to the Gross Domestic Product (GDP) of the Philippines. Nineteen percent of the company's total GDP contribution stems from innovation.

7.5B

Total GDP contribution (PHP)

1.4B

19% of GDP contribution is from Research and Development (PHP)

6,951

Total jobs created

6,749

Total jobs from supply chain and induced employees

203

Jobs arising from Novartis business activities


Employment

The company has opened up more employment opportunities for Filipinos and is providing broader regional leadership exposure to local talents

Novartis has been officially recognized by the Top Employers Institute as a Top Employer in the Philippines for three consecutive years (2021 - 2023). To become recognized as a Top Employer, an organization must demonstrate its commitment to putting its people first through its exceptional human resource (HR) policies. Top Employers Institute is the global authority on recognizing excellence in people practices.

Top Employer

for 3 consecutive years (2021-2023)

Energized for Life

a global wellbeing program that helps nurture the wellbeing of our employees at home and at work

Diversity, Equity, and Inclusion

promotes an equitable and inclusive workplace that values unique and curious minds


R&D

In 2022, Novartis invested a total of PHP 1.5 billion in 45 clinical trials, benefitting 1,086 patients in Respiratory, Cardiovascular, Metabolism, Immunology and dermatology, Ophthalmology, and Oncology. The company also established Centers of Excellence for Clinical Trials in local hospitals and research institutes.

1.2B

Investments in R&D (PHP)

45

Clinical trials

1,086

Patients in Local Trials


Access to medicines

In 2022, the full Novartis portfolio of medicines reached 800,000 Filipino patients. Filipino patients who took Novartis medicines gained a total of 5,361 quality-adjusted life-year (QALYs). QALY is a generic measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions. One QALY equates to one year in perfect health.

1.1B

Total Social Impact of Medicines (PHP)

800,000

Total Patients Reached

5,361

Total Quality Adjusted Life Years (QALY) gained


Support to national pandemic and calamity response

Novartis focused on supporting and protecting frontline workers and patients, and expanding the healthcare system's COVID-19 testing and treatment capacity.

The company donated over PHP 20 million worth of PPEs, test kits and food packs to help frontline workers. It collaborated with partner providers for home delivery of patients’ medicines.

With key stakeholders in the government and private sector, the company organized webinars to educate Filipinos on heart failure care amid the pandemic, and to address vaccine hesitancy.

20+m

Covid response donation (PHP)

Novartis donated PHP500,000 to support relief and rehabilitation of communities impacted by super typhoon Odette, the strongest typhoon to strike the Philippines in 2021 which disrupted the lives of more than seven million people.

0.5m

Donation to super typhoon Odette-impacted communities (PHP)

Through this donation, our partner PHAPCares Foundation distributed sacks of rice benefitting 2,000 families in Del Carmen, Surigao Del Norte. The donation will also cover the construction materials for the rehabilitation of a health center in Del Carmen, a 5th class municipality affected by typhoon Odette.